$RARE
Ultragenyx Pharmaceutical Inc.

2016 Q4 Form 10-Q Financial Statement

#000156459016028043 Filed on November 08, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2015 Q3
Revenue $5.000K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $19.81M $10.23M
YoY Change 70.92% 243.29%
% of Gross Profit
Research & Development $50.75M $29.70M
YoY Change 13.87% 131.13%
% of Gross Profit
Depreciation & Amortization $1.150M $440.0K
YoY Change 139.58% 131.58%
% of Gross Profit
Operating Expenses $70.55M $39.94M
YoY Change 25.63% 152.2%
Operating Profit
YoY Change
Interest Expense $910.0K $670.0K
YoY Change -1.09% 294.12%
% of Operating Profit
Other Income/Expense, Net -$1.620M $30.00K
YoY Change -8200.0% -314.29%
Pretax Income -$71.25M -$39.23M
YoY Change 29.03% 147.51%
Income Tax $40.00K
% Of Pretax Income
Net Earnings -$71.29M -$39.23M
YoY Change 29.1% 147.54%
Net Earnings / Revenue -1425740.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.748M -$1.025M
COMMON SHARES
Basic Shares Outstanding 40.86M 38.68M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $380.1M $448.4M
YoY Change -13.02% 122.86%
Cash & Equivalents $161.1M $166.7M
Short-Term Investments $219.0M $281.7M
Other Short-Term Assets $21.50M $12.30M
YoY Change 61.65% 123.64%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $401.7M $460.7M
YoY Change -10.78% 122.88%
LONG-TERM ASSETS
Property, Plant & Equipment $17.06M $6.300M
YoY Change 131.32% 142.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $118.0M $133.5M
YoY Change 18.83%
Other Assets $1.837M $1.600M
YoY Change 208.74% 0.0%
Total Long-Term Assets $138.9M $141.4M
YoY Change 27.04% 3266.67%
TOTAL ASSETS
Total Short-Term Assets $401.7M $460.7M
Total Long-Term Assets $138.9M $141.4M
Total Assets $540.6M $602.1M
YoY Change -3.39% 185.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.364M $4.400M
YoY Change 82.32% 4.76%
Accrued Expenses $54.55M $20.10M
YoY Change 120.12% 195.59%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $60.26M $24.70M
YoY Change 115.84% 122.52%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.393M $600.0K
YoY Change 1039.57% 20.0%
Total Long-Term Liabilities $6.393M $600.0K
YoY Change 1039.57% 20.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $60.26M $24.70M
Total Long-Term Liabilities $6.393M $600.0K
Total Liabilities $66.65M $25.40M
YoY Change 134.04% 118.97%
SHAREHOLDERS EQUITY
Retained Earnings -$530.5M
YoY Change 86.37%
Common Stock $41.00K
YoY Change 5.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $474.0M $576.8M
YoY Change
Total Liabilities & Shareholders Equity $540.6M $602.1M
YoY Change -3.39% 185.49%

Cashflow Statement

Concept 2016 Q4 2015 Q3
OPERATING ACTIVITIES
Net Income -$71.29M -$39.23M
YoY Change 29.1% 147.54%
Depreciation, Depletion And Amortization $1.150M $440.0K
YoY Change 139.58% 131.58%
Cash From Operating Activities -$47.68M -$30.60M
YoY Change 17.87% 177.43%
INVESTING ACTIVITIES
Capital Expenditures -$670.0K -$1.980M
YoY Change -65.28% 350.0%
Acquisitions
YoY Change
Other Investing Activities -$6.480M -$141.7M
YoY Change -79.52% 981.98%
Cash From Investing Activities -$7.150M -$143.7M
YoY Change -78.69% 960.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 74.94M 288.7M
YoY Change 8415.91% 377.03%
NET CHANGE
Cash From Operating Activities -47.68M -30.60M
Cash From Investing Activities -7.150M -143.7M
Cash From Financing Activities 74.94M 288.7M
Net Change In Cash 20.11M 114.3M
YoY Change -127.5% 218.23%
FREE CASH FLOW
Cash From Operating Activities -$47.68M -$30.60M
Capital Expenditures -$670.0K -$1.980M
Free Cash Flow -$47.01M -$28.62M
YoY Change 22.04% 170.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40859861
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
816578000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-868000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-284659000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
531090000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
128000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
559569000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38882394
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38882394
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1273000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-40000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3842000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.51
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36086598
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
22588000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-17000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
11765000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
135000
us-gaap Increase In Restricted Cash
IncreaseInRestrictedCash
1202000
us-gaap Increase In Restricted Cash
IncreaseInRestrictedCash
168000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-3700000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2267000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
904000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
98270000
rare Noncash License Fee From Collaboration Arrangement
NoncashLicenseFeeFromCollaborationArrangement
700000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-113295000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-65533000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9522000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3032000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
311523000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
477321000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
94289000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
63310000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
326228000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
158420000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-258791000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5597000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
142362000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24324000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
166686000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
33700000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
461158000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
26362000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3674000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
5528000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
63736000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
466686000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
48711000
us-gaap Nature Of Operations
NatureOfOperations
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Organization </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ultragenyx Pharmaceutical Inc. (the Company) is a biopharmaceutical company and was incorporated in California on April&#160;22, 2010. The Company subsequently reincorporated in the state of Delaware in June 2011. </p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.&#160;The Company is currently conducting a Phase 3 study of aceneuramic acid extended-release (Ace-ER) in patients with GNE myopathy, which is also known as hereditary inclusion body myopathy, a progressive muscle-wasting disorder; a Phase 3 study of recombinant human beta-glucuronidase (rhGUS) in patients with mucopolysaccharidosis 7 (MPS 7), a rare lysosomal storage disease; a Phase 2 clinical study for UX007 in patients with glucose transporter type-1 deficiency syndrome (Glut1 DS), a brain energy deficiency; a Phase 2 clinical study of UX007 in patients severely affected by long-chain fatty acid oxidation disorders (LC-FAOD), a genetic disorder in which the body is unable to convert long chain fatty acids into energy; and Phase 2 and Phase 3 studies of KRN23, an antibody targeting fibroblast growth factor 23, or FGF23, in patients with X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), both rare diseases that impair bone mineralization. The Company operates as one reportable segment.</p> <p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;</p></div>
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:13pt;margin-top:4pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities, and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. </p></div>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2016Q3 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
451030000
CY2015Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
514340000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
143000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
114000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3374031
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3838480
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4724824
CY2016Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
451030000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
515208000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
11000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
879000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
514340000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2016Q3 rare Research And Clinical Trial Expenses
ResearchAndClinicalTrialExpenses
16281000
CY2015Q4 rare Research And Clinical Trial Expenses
ResearchAndClinicalTrialExpenses
9764000
CY2016Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11818000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9423000
CY2016Q3 rare Liability Under Collaboration Arrangement
LiabilityUnderCollaborationArrangement
11358000
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4030000
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13694000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7896000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
34771000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15395000
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5345897

Files In Submission

Name View Source Status
0001564590-16-028043-index-headers.html Edgar Link pending
0001564590-16-028043-index.html Edgar Link pending
0001564590-16-028043.txt Edgar Link pending
0001564590-16-028043-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2016110723475990211431.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rare-10q_20160930.htm Edgar Link pending
rare-20160930.xml Edgar Link completed
rare-20160930.xsd Edgar Link pending
rare-20160930_cal.xml Edgar Link unprocessable
rare-20160930_def.xml Edgar Link unprocessable
rare-20160930_lab.xml Edgar Link unprocessable
rare-20160930_pre.xml Edgar Link unprocessable
rare-ex311_6.htm Edgar Link pending
rare-ex312_9.htm Edgar Link pending
rare-ex321_11.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending